Treatment of COVID 19-Repurposing drugs commonly used in dermatology.
Identifieur interne : 001399 ( Main/Corpus ); précédent : 001398; suivant : 001400Treatment of COVID 19-Repurposing drugs commonly used in dermatology.
Auteurs : Jelena Stojkovic-Filipovic ; Martina BosicSource :
- Dermatologic therapy [ 1529-8019 ] ; 2020.
English descriptors
- KwdEn :
- Antiviral Agents (therapeutic use), COVID-19 (complications), COVID-19 (drug therapy), Chloroquine (adverse effects), Chloroquine (therapeutic use), Dermatology (MeSH), Drug Repositioning (MeSH), Humans (MeSH), Hydroxychloroquine (adverse effects), Hydroxychloroquine (therapeutic use), SARS-CoV-2 (MeSH).
- MESH :
- chemical , adverse effects : Chloroquine, Hydroxychloroquine.
- chemical , therapeutic use : Antiviral Agents, Chloroquine, Hydroxychloroquine.
- complications : COVID-19.
- drug therapy : COVID-19.
- Dermatology, Drug Repositioning, Humans, SARS-CoV-2.
Abstract
For the last two decades, the outbreaks of diseases caused by coronaviruses and intermittent worldwide public health emergences have reminded us that they still represent a severe threat to global health. The recent outbreak of corona virus disease 19 (COVID-19) highlighted the urgent need for effective treatment, and initiated rapid search for therapies, able to counter the most severe disease effects. Many aspects of COVID-19 pathogenesis are unknown, but complex interplay of direct viral damage and immune response dysregulation is underline. Intensive research is undergoing for therapeutic targets of virus and high-efficiency and low toxicity targeted drugs. There is no available specific antiviral treatment of this disease, therefore repurposing of drugs already available for the treatment of other viral and autoimmune diseases has been a part of research efforts. Well known anti-inflammatory properties of chloroquine and hydroxychloroquine, agents widely used in dermatology, made them potential candidates for the treatment of COVID-19. We review pathogenesis and clinical characteristic of COVID-19, as well as treatment options that have been under evaluation in past several months. In addition, we focus more on chloroquine and hydroxychloroquine, their pharmacological properties, clinical utility, and current recommendations for their use in COVID-19.
DOI: 10.1111/dth.13829
PubMed: 32542964
PubMed Central: PMC7323008
Links to Exploration step
pubmed:32542964Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of COVID 19-Repurposing drugs commonly used in dermatology.</title><author><name sortKey="Stojkovic Filipovic, Jelena" sort="Stojkovic Filipovic, Jelena" uniqKey="Stojkovic Filipovic J" first="Jelena" last="Stojkovic-Filipovic">Jelena Stojkovic-Filipovic</name><affiliation><nlm:affiliation>Clinic of Dermatovenereology, Clinical Centre of Serbia, Belgrade, Serbia.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Dermatovenereology, School of Medicine, University of Belgrade, Belgrade, Serbia.</nlm:affiliation></affiliation></author><author><name sortKey="Bosic, Martina" sort="Bosic, Martina" uniqKey="Bosic M" first="Martina" last="Bosic">Martina Bosic</name><affiliation><nlm:affiliation>Institute of Pathology, School of Medicine, University of Belgrade, Belgrade, Serbia.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32542964</idno><idno type="pmid">32542964</idno><idno type="doi">10.1111/dth.13829</idno><idno type="pmc">PMC7323008</idno><idno type="wicri:Area/Main/Corpus">001399</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001399</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Treatment of COVID 19-Repurposing drugs commonly used in dermatology.</title><author><name sortKey="Stojkovic Filipovic, Jelena" sort="Stojkovic Filipovic, Jelena" uniqKey="Stojkovic Filipovic J" first="Jelena" last="Stojkovic-Filipovic">Jelena Stojkovic-Filipovic</name><affiliation><nlm:affiliation>Clinic of Dermatovenereology, Clinical Centre of Serbia, Belgrade, Serbia.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Dermatovenereology, School of Medicine, University of Belgrade, Belgrade, Serbia.</nlm:affiliation></affiliation></author><author><name sortKey="Bosic, Martina" sort="Bosic, Martina" uniqKey="Bosic M" first="Martina" last="Bosic">Martina Bosic</name><affiliation><nlm:affiliation>Institute of Pathology, School of Medicine, University of Belgrade, Belgrade, Serbia.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Dermatologic therapy</title><idno type="eISSN">1529-8019</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term><term>COVID-19 (complications)</term><term>COVID-19 (drug therapy)</term><term>Chloroquine (adverse effects)</term><term>Chloroquine (therapeutic use)</term><term>Dermatology (MeSH)</term><term>Drug Repositioning (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (adverse effects)</term><term>Hydroxychloroquine (therapeutic use)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Chloroquine</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Chloroquine</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Dermatology</term><term>Drug Repositioning</term><term>Humans</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">For the last two decades, the outbreaks of diseases caused by coronaviruses and intermittent worldwide public health emergences have reminded us that they still represent a severe threat to global health. The recent outbreak of corona virus disease 19 (COVID-19) highlighted the urgent need for effective treatment, and initiated rapid search for therapies, able to counter the most severe disease effects. Many aspects of COVID-19 pathogenesis are unknown, but complex interplay of direct viral damage and immune response dysregulation is underline. Intensive research is undergoing for therapeutic targets of virus and high-efficiency and low toxicity targeted drugs. There is no available specific antiviral treatment of this disease, therefore repurposing of drugs already available for the treatment of other viral and autoimmune diseases has been a part of research efforts. Well known anti-inflammatory properties of chloroquine and hydroxychloroquine, agents widely used in dermatology, made them potential candidates for the treatment of COVID-19. We review pathogenesis and clinical characteristic of COVID-19, as well as treatment options that have been under evaluation in past several months. In addition, we focus more on chloroquine and hydroxychloroquine, their pharmacological properties, clinical utility, and current recommendations for their use in COVID-19.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32542964</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1529-8019</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>09</Month></PubDate></JournalIssue><Title>Dermatologic therapy</Title><ISOAbbreviation>Dermatol Ther</ISOAbbreviation></Journal><ArticleTitle>Treatment of COVID 19-Repurposing drugs commonly used in dermatology.</ArticleTitle><Pagination><MedlinePgn>e13829</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/dth.13829</ELocationID><Abstract><AbstractText>For the last two decades, the outbreaks of diseases caused by coronaviruses and intermittent worldwide public health emergences have reminded us that they still represent a severe threat to global health. The recent outbreak of corona virus disease 19 (COVID-19) highlighted the urgent need for effective treatment, and initiated rapid search for therapies, able to counter the most severe disease effects. Many aspects of COVID-19 pathogenesis are unknown, but complex interplay of direct viral damage and immune response dysregulation is underline. Intensive research is undergoing for therapeutic targets of virus and high-efficiency and low toxicity targeted drugs. There is no available specific antiviral treatment of this disease, therefore repurposing of drugs already available for the treatment of other viral and autoimmune diseases has been a part of research efforts. Well known anti-inflammatory properties of chloroquine and hydroxychloroquine, agents widely used in dermatology, made them potential candidates for the treatment of COVID-19. We review pathogenesis and clinical characteristic of COVID-19, as well as treatment options that have been under evaluation in past several months. In addition, we focus more on chloroquine and hydroxychloroquine, their pharmacological properties, clinical utility, and current recommendations for their use in COVID-19.</AbstractText><CopyrightInformation>© 2020 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stojkovic-Filipovic</LastName><ForeName>Jelena</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7762-3199</Identifier><AffiliationInfo><Affiliation>Clinic of Dermatovenereology, Clinical Centre of Serbia, Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatovenereology, School of Medicine, University of Belgrade, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosic</LastName><ForeName>Martina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7113-2834</Identifier><AffiliationInfo><Affiliation>Institute of Pathology, School of Medicine, University of Belgrade, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dermatol Ther</MedlineTA><NlmUniqueID>9700070</NlmUniqueID><ISSNLinking>1396-0296</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>886U3H6UFF</RegistryNumber><NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003880" MajorTopicYN="Y">Dermatology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="Y">Drug Repositioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID 19</Keyword><Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword><Keyword MajorTopicYN="Y">antiviral treatment</Keyword><Keyword MajorTopicYN="Y">chloroquine</Keyword><Keyword MajorTopicYN="Y">hydroxychloroquine</Keyword><Keyword MajorTopicYN="Y">side effects</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>06</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32542964</ArticleId><ArticleId IdType="doi">10.1111/dth.13829</ArticleId><ArticleId IdType="pmc">PMC7323008</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733.</Citation></Reference><Reference><Citation>Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med J R Coll Physicians Lond. 2020;20(2):124-127.</Citation></Reference><Reference><Citation>Kang S, Peng W, Zhu Y, et al. Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment. Int J Antimicrob Agents. 2020;55:105950. https://doi.org/10.1016/j.ijantimicag.2020.105950.</Citation></Reference><Reference><Citation>Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020;92(6):568-576.</Citation></Reference><Reference><Citation>World Health Organization. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen. Accessed May 13, 2020.</Citation></Reference><Reference><Citation>Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.</Citation></Reference><Reference><Citation>World Health Organization. Coronavirus disease (COVID-19) Situation Report - 113. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed May 13, 2020.</Citation></Reference><Reference><Citation>Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Eurosurveill. 2020;25(4):2000058</Citation></Reference><Reference><Citation>Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.</Citation></Reference><Reference><Citation>Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091. https://doi.org/10.1136/bmj.m1295.</Citation></Reference><Reference><Citation>Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91-98.</Citation></Reference><Reference><Citation>Harapan H, Itoh N, Yufika A, et al. Coronavirus disease 2019 (COVID-19): a literature review. J Infect Public Health. 2020;13(5):667-673.</Citation></Reference><Reference><Citation>Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94(7):e00127-e00120. https://doi.org/10.1128/JVI.00127-20.</Citation></Reference><Reference><Citation>Qiu Y, Zhao YB, Wang Q, et al. Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2. Microbes Infect. 2020;22:221-225. https://doi.org/10.1016/j.micinf.2020.03.003.</Citation></Reference><Reference><Citation>Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260-1263.</Citation></Reference><Reference><Citation>Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;ciaa248. https://doi.org/10.1093/cid/ciaa248.</Citation></Reference><Reference><Citation>Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;e200994. https://doi.org/10.1001/jamainternmed.2020.0994.</Citation></Reference><Reference><Citation>McGonagle D, Sharif K, O'Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020;19(6):102537. https://doi.org/10.1016/j.autrev.2020.102537.</Citation></Reference><Reference><Citation>Zhou M, Zhang X, Qu J. Coronavirus disease 2019 (COVID-19): a clinical update. Front Med. 2020;14(2):126-135.</Citation></Reference><Reference><Citation>Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7(1):4. https://doi.org/10.1186/s40779-020-0233-6.</Citation></Reference><Reference><Citation>Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med. 2020;35(5):1545-1549.</Citation></Reference><Reference><Citation>Raoult D, Zumla A, Locatelli F, Ippolito G, Kroemer G. Coronavirus infections: epidemiological, clinical and immunological features and hypotheses. Cell Stress. 2020;4(4):66-75.</Citation></Reference><Reference><Citation>Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-271.</Citation></Reference><Reference><Citation>Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Rev Panam Salud Pública. 2020;44:1.</Citation></Reference><Reference><Citation>Pan Y, Guan H, Zhou S, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. Eur Radiol. 2020;30(6):3306-3309.</Citation></Reference><Reference><Citation>World Health Organization. Clinical Management of COVID-19. Interim guidance. https://www.who.int/publications-detail/clinical-management-of-covid-19. Accessed May 27, 2020.</Citation></Reference><Reference><Citation>Gharebaghi R, Heidary F, Moradi M, Parvizi M. Metronidazole a potential novel addition to the COVID-19 treatment regimen. SSRN Electron J. 2020;8(1):e40.</Citation></Reference><Reference><Citation>Parhizgar AR. Introducing new antimalarial analogues of chloroquine and amodiaquine: a narrative review. Iran J Med Sci. 2017;42(2):115-128.</Citation></Reference><Reference><Citation>Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155-166.</Citation></Reference><Reference><Citation>Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020;55:105938. https://doi.org/10.1016/j.ijantimicag.2020.105938.</Citation></Reference><Reference><Citation>Maiberger MP, Nunley JR, Wolverton SE. Other systemic drugs. In: Bolognia JL, Schaffer JV, Cerroni L, et al., eds. Dermatology. 4th ed.The Netherlands: Elsevier; 2018:2280-2281.</Citation></Reference><Reference><Citation>Sharma AN, Mesinkovska NA, Paravar T. Characterizing the adverse dermatologic effects of hydroxychloroquine: a systematic review. J Am Acad Dermatol. 2020;S0190-9622(20):30564-30568. https://doi.org/10.1016/j.jaad.2020.04.024.</Citation></Reference><Reference><Citation>Wu S-F, Chang C-B, Hsu J-M, et al. Hydroxychloroquine inhibits CD154 expression in CD4(+) T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling. Arthritis Res Ther. 2017;19(1):183.</Citation></Reference><Reference><Citation>Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents. 2007;30(4):297-308.</Citation></Reference><Reference><Citation>Boelaert JR, Piette J, Sperber K. The potential place of chloroquine in the treatment of HIV-1-infected patients. J Clin Virol. 2001;20(3):137-140.</Citation></Reference><Reference><Citation>Eng EO, Chew JSW, Jin PL, Chua RCS. In vitro inhibition of human influenza A virus replication by chloroquine. Virol J. 2006;3:39.</Citation></Reference><Reference><Citation>Paton NI, Lee L, Xu Y, et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect Dis. 2011;11(9):677-683.</Citation></Reference><Reference><Citation>Yan Y, Zou Z, Sun Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res. 2013;23(2):300-302.</Citation></Reference><Reference><Citation>Bishop NE. Examination of potential inhibitors of hepatitis A virus uncoating. Intervirology. 1998;41(6):261-271.</Citation></Reference><Reference><Citation>Mizui T, Yamashina S, Tanida I, et al. Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy. J Gastroenterol. 2010;45(2):195-203.</Citation></Reference><Reference><Citation>Delogu I, De Lamballerie X. Chikungunya disease and chloroquine treatment. J Med Virol. 2011;83(6):1058-1059.</Citation></Reference><Reference><Citation>Farias KJS, Machado PRL, de Almeida Junior RF, de Aquino AA, da Fonseca BAL. Chloroquine interferes with dengue-2 virus replication in U937 cells. Microbiol Immunol. 2014;58(6):318-326.</Citation></Reference><Reference><Citation>Delvecchio R, Higa LM, Pezzuto P, et al. Chloroquine, an endocytosis blocking agent, inhibits zika virus infection in different cell models. Viruses. 2016;8(12):322</Citation></Reference><Reference><Citation>Ferraris O, Moroso M, Pernet O, et al. Evaluation of Crimean-Congo hemorrhagic fever virus in vitro inhibition by chloroquine and chlorpromazine, two FDA approved molecules. Antiviral Res. 2015;118:75-81.</Citation></Reference><Reference><Citation>Dowall SD, Bosworth A, Watson R, et al. Chloroquine inhibited ebola virus replication in vitro but failed to protect against infection and disease in the in vivo Guinea pig model. J Gen Virol. 2015;96(12):3484-3492.</Citation></Reference><Reference><Citation>Kronenberger P, Vrijsen R, Boeyé A. Chloroquine induces empty capsid formation during poliovirus eclipse. J Virol. 1991;65(12):7008-7011.</Citation></Reference><Reference><Citation>Tsiang H, Superti F. Ammonium chloride and chloroquine inhibit rabies virus infection in neuroblastoma cells. Brief Report. Arch Virol. 1984;81(3-4):377-382.</Citation></Reference><Reference><Citation>Kouroumalis EA, Koskinas J. Treatment of chronic active hepatitis B (CAH B) with chloroquine: a preliminary report. Ann Acad Med Singapore. 1986;15(2):149-152.</Citation></Reference><Reference><Citation>Koyama AH, Uchida T. Inhibition of multiplication of herpes simplex virus type 1 by ammonium chloride and chloroquine. Virology. 1984;138(2):332-335.</Citation></Reference><Reference><Citation>Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases. Lancet Infect Dis. 2003;3(11):722-727.</Citation></Reference><Reference><Citation>Keyaerts E, Li S, Vijgen L, et al. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother. 2009;53(8):3416-3421.</Citation></Reference><Reference><Citation>Kono M, Tatsumi K, Imai AM, Saito K, Kuriyama T, Shirasawa H. Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK. Antiviral Res. 2008;77(2):150-152.</Citation></Reference><Reference><Citation>Wang P-H, Cheng Y. Increasing host cellular receptor-angiotensin-converting enzyme 2 (ACE2) expression by coronavirus may facilitate 2019-nCoV infection. bioRxiv. 2020. https://doi.org/10.1101/2020.02.24.963348.</Citation></Reference><Reference><Citation>Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69.</Citation></Reference><Reference><Citation>Savarino A, Bounavoglia C, Norelli S, Di Trani L, Cassone A. Potential therapies for coronaviruses. Expert Opin Ther Pat. 2006;16(9):1269-1288.</Citation></Reference><Reference><Citation>Sandeep S, McGregor K. Energetics Based Modeling of Hydroxychloroquine and Azithromycin Binding to the SARS-CoV-2 Spike (S)Protein - ACE2 Complex. 2020. doi:https://doi.org/10.26434/chemrxiv.12015792.v2.</Citation></Reference><Reference><Citation>Kwiek JJ, Haystead TAJ, Rudolph J. Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines. Biochemistry. 2004;43(15):4538-4547.</Citation></Reference><Reference><Citation>Simmons G, Bertram S, Glowacka I, et al. Different host cell proteases activate the SARS-coronavirus spike-protein for cell-cell and virus-cell fusion. Virology. 2011;413(2):265-274.</Citation></Reference><Reference><Citation>Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6(1):1-4.</Citation></Reference><Reference><Citation>Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72-73.</Citation></Reference><Reference><Citation>Huang M, Li M, Xiao F, et al. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. National Science Review, medRxiv. 2020. https://doi.org/10.1093/nsr/nwaa113.</Citation></Reference><Reference><Citation>Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020;3(4):e208857. https://doi.org/10.1001/jamanetworkopen.2020.8857.</Citation></Reference><Reference><Citation>Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases, Clin Infect Dis. 2020;ciaa237. https://doi.org/10.1093/cid/ciaa237.</Citation></Reference><Reference><Citation>Membrillo FJ, Ramírez-Olivencia G, Estébanez M, et al. Early hydroxychloroquine is associated with an increase of survival in COVID-19 patients: an observational study. Preprints. 2020;2020050057. https://doi.org/10.20944/PREPRINTS202005.0057.V2.</Citation></Reference><Reference><Citation>Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv. 2020. https://doi.org/10.1101/2020.03.22.20040758.</Citation></Reference><Reference><Citation>Yu B, Wang DW, Li C. Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19. medRxiv. 2020. https://doi.org/10.1101/2020.04.27.20073379.</Citation></Reference><Reference><Citation>Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849. https://doi.org/10.1136/bmj.m1849.</Citation></Reference><Reference><Citation>Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis. 2020;34:101663. https://doi.org/10.1016/j.tmaid.2020.101663.</Citation></Reference><Reference><Citation>Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;105949. https://doi.org/10.1016/j.ijantimicag.2020.105949.</Citation></Reference><Reference><Citation>Million M, Lagier JC, Gautret P, et al. Full-length title: early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis. 2020;101738. https://doi.org/10.1016/j.tmaid.2020.101738.</Citation></Reference><Reference><Citation>Barbosa Esper R, Souza da Silva R, Teiichi Costa Oikawa F, et al. Empirical Treatment with Hydroxychloroquine and Azithromycin for Suspected Cases of COVID-19 Followed-up by Telemedicine. https://pgibertie.files.wordpress.com/2020/04/2020.04.15-journal-manuscript-final.pdf. Accessed March 23, 2020.</Citation></Reference><Reference><Citation>Released by National Health Commission & National Administration of Traditional Chinese Medicine on March 3, 2020. Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). Chin Med J (Engl). 2020;133(9):1087-1095. https://journals.lww.com/cmj/Fulltext/2020/05050/Diagnosis_and_Treatment_Protocol_for_Novel.13.aspx.</Citation></Reference><Reference><Citation>Società Italiana di Malattie Infettive e Tropicali. Gestione Domiciliare Della Terapia Precoce COVID 19 Documento SIMIT condiviso da FIMMG e SIMG, Versione 27 Marzo 2020. http://www.simit.org/medias/1588-flow-chart-gestionale-terapia-domiciliare-precoce-covid-19-versione-27-marzo-2020.pdf. Accessed May 13, 2020.</Citation></Reference><Reference><Citation>Spanish Ministry of Health. https://www.aemps.gob.es/la-aemps/ultima-informacion-de-la-aemps-acerca-del-covid-19/tratamientos-disponibles-para-el-manejo-de-la-infeccion-respiratoria-por-sars-cov-2/. Accessed May 14, 2020.</Citation></Reference><Reference><Citation>The Dutch Working Party on Antibiotic Policy. https://swab.nl/nl/covid-19. Accessed May 13, 2020.</Citation></Reference><Reference><Citation>Interim clinical guidance for adults with suspected or confirmed COVID-19 in Belgium. https://covid-19.sciensano.be/sites/default/files/Covid19/COVID-19_InterimGuidelines_Treatment_ENG.pdf. Accessed May 14, 2020.</Citation></Reference><Reference><Citation>Agence nationale de securite du medicament et des produits de sante. Protocole d'utilisation Therapeutique 30 mars 2020 Hydroxychloroquine Infection par le coronavirus SARS-CoV-2 (maladie COVID-19). https://splf.fr/centre-de-documentation-covid-19/ansm-protocole-utilisation-therapeutique-hydroxy-chloroquine-30-03-20/. Accessed May 14, 2020.</Citation></Reference><Reference><Citation>Hellenic Thoracic Society. Management algorithm for patients with confirmed COVID-19 in hospital setting. hts.org.gr/assets/2nd argorithm.gif. Accessed May 14, 2020.</Citation></Reference><Reference><Citation>General Directorate of Public Health. COVID-19 (SARS-CoV-2 ENFEKSİYONU) REHBERİ. https://covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf. Accessed May 14, 2020.</Citation></Reference><Reference><Citation>Australian National COVID-19 Clinical Evidence Taskforce. Australian guidelines for the clinical care of people with COVID-19. https://app.magicapp.org/#/guideline/4223. Accessed May 14, 2020.</Citation></Reference><Reference><Citation>Singapore National Centre for Infectious Diseases. Interim Treatment Guidelines for COVID-19 (Version 1.0, dated April 2, 2020). https://www.ncid.sg/Health-Professionals/Diseases-and-Conditions/Pages/COVID-19.aspx. Accessed May 14, 2020.</Citation></Reference><Reference><Citation>USA National Institute of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf. Accessed May 14, 2020.</Citation></Reference><Reference><Citation>Mount Sinai Health System. Mount Sinai Health System Treatment Guidelines for SARS-CoV-2 Infection (COVID-19). https://www.mountsinai.org/files/MSHealth/Assets/HS/About/Coronavirus/MSHS-Treatment-Guidelines-COVID.pdf. Accessed May 14, 2020.</Citation></Reference><Reference><Citation>Chico RM, Chandramohan D. Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy. Expert Opin Drug Metab Toxicol. 2011;7(9):1153-1167.</Citation></Reference><Reference><Citation>Bernstein HN. Ocular safety of hydroxychloroquine. Ann Ophthalmol. 1991;23(8):292-296.</Citation></Reference><Reference><Citation>Silva JA, Silva MB, Skare TL. Chloroquine and QTc interval. Clin Exp Rheumatol. 2007;25(5):795.</Citation></Reference><Reference><Citation>Saleh M, Gabriels J, Chang D, et al. The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection. Circ Arrhythm Electrophysiol. 2020;13(6):e008662. https://doi.org/10.1161/CIRCEP.120.008662.</Citation></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001399 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001399 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32542964
|texte= Treatment of COVID 19-Repurposing drugs commonly used in dermatology.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32542964" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |